{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T15:27:51Z","timestamp":1785338871791,"version":"3.55.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s00467-016-3474-6","type":"journal-article","created":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T21:47:57Z","timestamp":1472766477000},"page":"1137-1144","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Treatment of renal angiomyolipoma in tuberous sclerosis complex (TSC) patients"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3845-211X","authenticated-orcid":false,"given":"S.","family":"Brakemeier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Bachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Budde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,9,1]]},"reference":[{"key":"3474_CR1","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1053\/j.ajkd.2011.10.013","volume":"59","author":"K Budde","year":"2012","unstructured":"Budde K, Gaedeke J (2012) Tuberous sclerosis complex\u2013associated angiomyolipomas: focus on mTOR inhibition. Am J Kidney Dis 59:276\u2013283","journal-title":"Am J Kidney Dis"},{"key":"3474_CR2","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMra055323","volume":"355","author":"PB Crino","year":"2006","unstructured":"Crino PB, Nathanson KL, Henske EP (2006) The tuberous sclerosis complex. N Engl J Med 355:1345\u20131356","journal-title":"N Engl J Med"},{"key":"3474_CR3","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1177\/088307380001501003","volume":"15","author":"S Jozwiak","year":"2000","unstructured":"Jozwiak S, Schwartz RA, Janniger CK, Bielicka-Cymerman J (2000) Usefulness of diagnostic criteria of tuberous sclerosis complex in pediatric patients. J Child Neurol 15:652\u2013659","journal-title":"J Child Neurol"},{"key":"3474_CR4","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.pediatrneurol.2013.08.001","volume":"49","author":"H Northrup","year":"2013","unstructured":"Northrup H, Krueger DA (2013) Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 Iinternational Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol 49:243\u2013254","journal-title":"Pediatr Neurol"},{"key":"3474_CR5","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.pediatrneurol.2013.08.002","volume":"49","author":"DA Krueger","year":"2013","unstructured":"Krueger DA, Northrup H (2013) Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol 49:255\u2013265","journal-title":"Pediatr Neurol"},{"key":"3474_CR6","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(08)61279-9","volume":"372","author":"P Curatolo","year":"2008","unstructured":"Curatolo P, Bombardieri R, Jozwiak S (2008) Tuberous sclerosis. Lancet 372:657\u2013668","journal-title":"Lancet"},{"key":"3474_CR7","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/j.1523-1755.2004.00838.x","volume":"66","author":"JJ Bissler","year":"2004","unstructured":"Bissler JJ, Kingswood JC (2004) Renal angiomyolipomata. Kidney Int 66:924\u2013934","journal-title":"Kidney Int"},{"key":"3474_CR8","doi-asserted-by":"crossref","unstructured":"Yamakado K, Tanaka N, Nakagawa T, Kobayashi S, Yanagawa M, Takeda K (2002) Renal angiomyolipoma: relationships between tumor size, aneurysm formation, and rupture. Radiology 225:78\u201382","DOI":"10.1148\/radiol.2251011477"},{"key":"3474_CR9","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1053\/j.ajkd.2015.05.016","volume":"66","author":"MJ Eijkemans","year":"2015","unstructured":"Eijkemans MJ, van der Wal W, Reijnders LJ, Roes KC, van Waalwijk van Doorn-Khosrovani SB, Pelletier C, Magestro M, Zonnenberg B (2015) Long-term follow-up assessing renal angiomyolipoma treatment patterns, morbidity, and mortality: an observational study in tuberous sclerosis complex patients in the Netherlands. Am J Kidney Dis 66:638\u2013645","journal-title":"Am J Kidney Dis"},{"key":"3474_CR10","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1159\/000320891","volume":"118","author":"BP Dixon","year":"2011","unstructured":"Dixon BP, Hulbert JC, Bissler JJ (2011) Tuberous sclerosis complex renal disease. Nephron Exp Nephrol 118:e15\u2013e20","journal-title":"Nephron Exp Nephrol"},{"key":"3474_CR11","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1185\/03007995.2015.1060212","volume":"31","author":"J Bissler","year":"2015","unstructured":"Bissler J, Cappell K, Charles H, Song X, Liu Z, Prestifilippo J, Hulbert J (2015) Rates of interventional procedures in patients with tuberous sclerosis complex-related renal angiomyolipoma. Curr Med Res Opin 31:1501\u20131507","journal-title":"Curr Med Res Opin"},{"key":"3474_CR12","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S0025-6196(12)61196-3","volume":"66","author":"CW Shepherd","year":"1991","unstructured":"Shepherd CW, Gomez MR, Lie JT, Crowson CS (1991) Causes of death in patients with tuberous sclerosis. Mayo Clin Proc 66:792\u2013796","journal-title":"Mayo Clin Proc"},{"key":"3474_CR13","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1464-410X.2004.05046.x","volume":"94","author":"FJ O\u2019Callaghan","year":"2004","unstructured":"O\u2019Callaghan FJ, Noakes MJ, Martyn CN, Osborne JP (2004) An epidemiological study of renal pathology in tuberous sclerosis complex. BJU Int 94:853\u2013857","journal-title":"BJU Int"},{"key":"3474_CR14","doi-asserted-by":"crossref","unstructured":"Brook-Carter PT, Peral B, Ward CJ, Thompson P, Hughes J, Maheshwar MM, Nellist M, Gamble V, Harris PC, Sampson JR (1994) Deletion of the TSC2 and PKD1 genes associated with severe infantile polycystic kidney disease\u2013a contiguous gene syndrome. Nat Genet 8:328\u2013332","DOI":"10.1038\/ng1294-328"},{"key":"3474_CR15","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/sj.ejhg.5201625","volume":"14","author":"JRW Yates","year":"2006","unstructured":"Yates JRW (2006) Tuberous sclerosis. Eur J Hum Genet 14:1065\u20131073","journal-title":"Eur J Hum Genet"},{"key":"3474_CR16","doi-asserted-by":"crossref","unstructured":"Kozlowski P, Roberts P, Dabora S, Franz D, Bissler J, Northrup H, Au KS, Lazarus R, Domanska-Pakiela D, Kotulska K, Jozwiak S, Kwiatkowski DJ (2007) Identification of 54 large deletions\/duplications in TSC1 and TSC2 using MLPA, and genotype-phenotype correlations. Hum Genet 121(3\u20134):389\u2013400","DOI":"10.1007\/s00439-006-0308-9"},{"key":"3474_CR17","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s00247-014-3147-1","volume":"45","author":"SJ Back","year":"2015","unstructured":"Back SJ, Andronikou S, Kilborn T, Kaplan BS, Darge K (2015) Imaging features of tuberous sclerosis complex with autosomal-dominant polycystic kidney disease: a contiguous gene syndrome. Pediatr Radiol 45:386\u2013395","journal-title":"Pediatr Radiol"},{"key":"3474_CR18","doi-asserted-by":"crossref","unstructured":"Consugar MB, Wong WC, Lundquist PA, Rossetti S, Kubly VJ, Walker DL, Rangel LI, Aspinwall R, Niaudet WP, Ozen S, David A, Velinov M, Bergstralh EJ, Bae KT, Chapman AB, Guay-Woodford LM, Grantham JJ, Torres VE, Sampson JR, Dawson BD, Harris PC; CRISP Consortium (2008) Characterization of large rearrangements in autosomal dominant polycystic kidney disease and the PKD1\/TSC2 contiguous gene syndrome. Kidney Int 74:1468\u20131479","DOI":"10.1038\/ki.2008.485"},{"key":"3474_CR19","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1093\/ndt\/14.4.988","volume":"14","author":"A Clarke","year":"1999","unstructured":"Clarke A, Hancock E, Kingswood C, Osborne JP (1999) End-stage renal failure in adults with the tuberous sclerosis complex. Nephrol Dial Transplant 14:988\u2013991","journal-title":"Nephrol Dial Transplant"},{"key":"3474_CR20","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.3111\/13696998.2015.1075995","volume":"18","author":"F Vekeman","year":"2015","unstructured":"Vekeman F, Magestro M, Karner P, Duh MS, Nichols T, van Waalwijk van Doorn-Khosrovani Barjesteh S, Zonnenberg BA (2015) Kidney involvement in tuberous sclerosis complex: the impact on healthcare resource use and costs. J Med Econ 18:1060\u20131070","journal-title":"J Med Econ"},{"key":"3474_CR21","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1128\/MCB.00289-08","volume":"28","author":"J Huang","year":"2008","unstructured":"Huang J, Dibble CC, Matsuzaki M, Manning BD (2008) The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol Cell Biol 28:4104\u20134115","journal-title":"Mol Cell Biol"},{"key":"3474_CR22","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1093\/med\/9780199592548.003.0330","volume-title":"Oxford textbook of clinical nephrology","author":"BP Dixon","year":"2015","unstructured":"Dixon BP, Kingswood JC, Bissler JJ (2015) Tuberous sclerosis complex renal disease. In: Turner N, Lameire N, Goldsmith DJ, Winearls CG, Himmelfarb J, Remuzzi G (eds) Oxford textbook of clinical nephrology, 4th edn. Oxford University Press, Oxford, pp 2732\u20132738","edition":"4"},{"key":"3474_CR23","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1172\/JCI58709","volume":"122","author":"EP Henske","year":"2012","unstructured":"Henske EP, McCormack FX (2012) Lymphangioleiomyomatosis - a wolf in sheep\u2019s clothing. J Clin Invest 122:3807\u20133816","journal-title":"J Clin Invest"},{"key":"3474_CR24","doi-asserted-by":"crossref","unstructured":"McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch JP 3rd, Goldberg HJ, Young LR, Kinder BW, Downey GP, Sullivan EJ, Colby TV, McKay RT, Cohen MM, Korbee L, Taveira-DaSilva AM, Lee HS, Krischer JP, Trapnell BC; National Institutes of Health Rare Lung Diseases Consortium; MILES Trial Group (2011) Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 364:1595\u20131606","DOI":"10.1056\/NEJMoa1100391"},{"key":"3474_CR25","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1158\/1078-0432.CCR-11-0445","volume":"17","author":"DM Davies","year":"2011","unstructured":"Davies DM, de Vries PJ, Johnson SR, McCartney DL, Cox JA, Serra AL, Watson PC, Howe CJ, Doyle T, Pointon K, Cross JJ, Tattersfield AE, Kingswood JC, Sampson JR (2011) Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin Cancer Res 17:4071\u20134081","journal-title":"Clin Cancer Res"},{"key":"3474_CR26","doi-asserted-by":"crossref","first-page":"797","DOI":"10.7326\/0003-4819-154-12-201106210-00007","volume":"154","author":"AM Taveira-DaSilva","year":"2011","unstructured":"Taveira-DaSilva AM, Hathaway O, Stylianou M, Moss J (2011) Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus. Ann Intern Med 154:797\u2013805, W-292-3","journal-title":"Ann Intern Med"},{"key":"3474_CR27","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","volume":"381","author":"DN Franz","year":"2013","unstructured":"Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ, Whittemore VH, Thiele EA, Ford JP, Shah G, Cauwel H, Lebwohl D, Sahmoud T, Jozwiak S (2013) Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 381:125\u2013132","journal-title":"Lancet"},{"key":"3474_CR28","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","volume":"363","author":"DA Krueger","year":"2010","unstructured":"Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, Wilson KA, Byars A, Sahmoud T, Franz DN (2010) Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 363:1801\u20131811","journal-title":"N Engl J Med"},{"key":"3474_CR29","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","volume":"381","author":"JJ Bissler","year":"2013","unstructured":"Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, Sauter M, Nonomura N, Brakemeier S, de Vries PJ, Whittemore VH, Chen D, Sahmoud T, Shah G, Lincy J, Lebwohl D, Budde K (2013) Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 381:817\u2013824","journal-title":"Lancet"},{"key":"3474_CR30","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/ndt\/gfv249","volume":"31","author":"JJ Bissler","year":"2016","unstructured":"Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, Sauter M, Nonomura N, Brakemeier S, de Vries PJ, Berkowitz N, Miao S, Segal S, Peyrard S, Budde K (2016) Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial. Nephrol Dial Transplant 31:111\u2013119","journal-title":"Nephrol Dial Transplant"},{"key":"3474_CR31","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.jaad.2015.07.018","volume":"73","author":"N Nathan","year":"2015","unstructured":"Nathan N, Wang JA, Li S, Cowen EW, Haughey M, Moss J, Darling TN (2015) Improvement of tuberous sclerosis complex (TSC) skin tumors during long-term treatment with oral sirolimus. J Am Acad Dermatol 73:802\u2013808","journal-title":"J Am Acad Dermatol"},{"key":"3474_CR32","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa063564","volume":"358","author":"JJ Bissler","year":"2008","unstructured":"Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, Schmithorst VJ, Laor T, Brody AS, Bean J, Salisbury S, Franz DN (2008) Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 358:140\u2013151","journal-title":"N Engl J Med"},{"key":"3474_CR33","doi-asserted-by":"crossref","unstructured":"Franz DN, Brody A, Meyer C, Leonard J, Chuck G, Dabora S, Sethuraman G, Colby TV, Kwiatkowski DJ, McCormack FX (2001) Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis. Am J Respir Crit Care Med 164:661e8","DOI":"10.1164\/ajrccm.164.4.2011025"},{"key":"3474_CR34","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1093\/ndt\/gft009","volume":"28","author":"Y Pirson","year":"2013","unstructured":"Pirson Y (2013) Tuberous sclerosis complex-associated kidney angiomyolipoma: from contemplation to action. Nephrol Dial Transplant 28:1680\u20131685","journal-title":"Nephrol Dial Transplant"},{"key":"3474_CR35","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1093\/hmg\/ddu597","volume":"24","author":"ME Tyburczy","year":"2014","unstructured":"Tyburczy ME, Jozwiak S, Malinowska IA, Chekaluk Y, Pugh TJ, Wu CL, Nussbaum RL, Seepo S, Dzik T, Kotulska K, Kwiatkowski DJ (2014) A shower of second hit events as the cause of multifocal renal cell carcinoma in tuberous sclerosis complex. Hum Mol Genet 24:1836\u20131842","journal-title":"Hum Mol Genet"},{"key":"3474_CR36","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1097\/PAS.0000000000000248","volume":"38","author":"J Guo","year":"2014","unstructured":"Guo J, Tretiakova MS, Troxell ML, Osunkoya AO, Fadare O, Sangoi AR, Shen SS, Lopez-Beltran A, Mehra R, Heider A, Higgins JP, Harik LR, Leroy X, Gill AJ, Trpkov K, Campbell SC, Przybycin C, Magi-Galluzzi C, McKenney JK (2014) Tuberous sclerosis-associated renal cell carcinoma: a clinicopathologic study of 57 separate carcinomas in 18 patients. Am J Surg Pathol 38:1457\u20131467","journal-title":"Am J Surg Pathol"},{"key":"3474_CR37","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12881-015-0185-y","volume":"16","author":"C Cabrera-L\u00f3pez","year":"2015","unstructured":"Cabrera-L\u00f3pez C, Bullich G, Mart\u00ed T, Catal\u00e0 V, Ballar\u00edn J, Bissler JJ, Harris PC, Ars E, Torra R (2015) Insight into response to mTOR inhibition when PKD1 and TSC2 are mutated. BMC Med Genet 16:39","journal-title":"BMC Med Genet"},{"key":"3474_CR38","unstructured":"Aguiar PV, Campistol JM, Diekmann F (2015) Safety of mTOR inhibitors in adult solid organ transplantation. Expert Opin Drug Saf"},{"key":"3474_CR39","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1111\/bph.12749","volume":"171","author":"M Moschetta","year":"2014","unstructured":"Moschetta M, Reale A, Marasco C, Vacca A, Carrat\u00f9 MR (2014) Therapeutic targeting of the mTOR-signalling pathway in cancer: benefits and limitations. Br J Pharmacol 171:3801\u20133813","journal-title":"Br J Pharmacol"},{"key":"3474_CR40","doi-asserted-by":"crossref","unstructured":"Budde K, Zonnenberg BA, Frost M, Cheung W, Urva S, Brechenmacher T, Stein K, Chen D, Kingswood C, Bissler JJ (2015) Pharmacokinetics and pharmacodynamics of everolimus in patients with renal angiomyolipoma and tuberous sclerosis complex or lymphangioleiomyomatosis. Br J Clin Pharm 81:958\u2013970","DOI":"10.1111\/bcp.12834"},{"key":"3474_CR41","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.1542\/peds.2012-3607","volume":"132","author":"K Kotulska","year":"2013","unstructured":"Kotulska K, Borkowska J, Jozwiak S (2013) Possible prevention of tuberous sclerosis complex lesions. Pediatrics 132:e239\u2013e242","journal-title":"Pediatrics"},{"key":"3474_CR42","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ejpn.2013.06.002","volume":"17","author":"G Wiegand","year":"2013","unstructured":"Wiegand G, May TW, Ostertag P, Boor R, Stephani U, Franz DN (2013) Everolimus in tuberous sclerosis patients with intractable epilepsy: a treatment option? Eur J Paediatr Neurol 17:631\u2013638","journal-title":"Eur J Paediatr Neurol"},{"key":"3474_CR43","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.jpeds.2013.12.053","volume":"164","author":"M Cardamone","year":"2014","unstructured":"Cardamone M, Flanagan D, Mowat D, Kennedy SE, Chopra M, Lawson JA (2014) Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex. J Pediatr 164:1195\u20131200","journal-title":"J Pediatr"},{"key":"3474_CR44","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.pediatrneurol.2014.10.028","volume":"52","author":"P Curatolo","year":"2015","unstructured":"Curatolo P (2015) Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy. Pediatr Neurol 52:281\u2013289","journal-title":"Pediatr Neurol"},{"key":"3474_CR45","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.pharep.2014.12.017","volume":"67","author":"K Sadowski","year":"2015","unstructured":"Sadowski K, Kotulska-J\u00f3\u017awiak K, J\u00f3\u017awiak S (2015) Role of mTOR inhibitors in epilepsy treatment. Pharmacol Rep 67:636\u2013646","journal-title":"Pharmacol Rep"},{"key":"3474_CR46","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/ana.23960","volume":"74","author":"DA Krueger","year":"2013","unstructured":"Krueger DA, Wilfong AA, Holland-Bouley K, Anderson AE, Agricola K, Tudor C, Mays M, Lopez CM, Kim MO, Franz DN (2013) Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Ann Neurol 74:679\u2013687","journal-title":"Ann Neurol"},{"key":"3474_CR47","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2215\/CJN.07371009","volume":"5","author":"M Duerr","year":"2010","unstructured":"Duerr M, Glander P, Diekmann F, Dragun D, Neumayer HH, Budde K (2010) Increased incidence of angioedema with ACE inhibitors in combination with mTOR inhibitors in kidney transplant recipients. Clin J Am Soc Nephrol 5:703\u2013708","journal-title":"Clin J Am Soc Nephrol"},{"key":"3474_CR48","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s13023-014-0182-9","volume":"9","author":"JC Kingswood","year":"2014","unstructured":"Kingswood JC, Bruzzi P, Curatolo P, de Vries PJ, Fladrowski C, Hertzberg C, Jansen AC, Jozwiak S, Nabbout R, Sauter M, Touraine R, O\u2019Callaghan F, Zonnenberg B, Crippa S, Comis S, d\u2019Aug\u00e8res GB, Belousova E, Carter T, Cottin V, Dahlin M, Ferreira JC, Macaya A, Benedik MP, Sander V, Youroukos S, Castellana R, Ulker B, Feucht M (2014) TOSCA - first international registry to address knowledge gaps in the natural history and management of tuberous sclerosis complex. Orphanet J Rare Dis 9:182","journal-title":"Orphanet J Rare Dis"},{"key":"3474_CR49","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.pediatrneurol.2014.10.024","volume":"53","author":"LH Tran","year":"2015","unstructured":"Tran LH, Zupanc ML (2015) Long-term everolimus treatment in individuals with tuberous sclerosis complex: a review of the current literature. Pediatr Neurol 53:23\u201330","journal-title":"Pediatr Neurol"},{"key":"3474_CR50","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/jcph.428","volume":"55","author":"MJ Somers","year":"2015","unstructured":"Somers MJ, Paul E (2015) Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation. J Clin Pharmacol 55:368\u2013376","journal-title":"J Clin Pharmacol"},{"key":"3474_CR51","doi-asserted-by":"crossref","unstructured":"Kingswood C, Bolton P, Crawford P, Harland C, Johnson SR, Sampson JR, Shepherd C, Spink J, Demuth D, Lucchese L, Nasuti P, Gray E, Pinnegar A, Magestro M (2015) The clinical profile of tuberous sclerosis complex (TSC) in the United Kingdom: a retrospective cohort study in the Clinical Practice Research Datalink (CPRD). Eur J Paediatr Neurol","DOI":"10.1016\/j.ejpn.2015.11.011"},{"key":"3474_CR52","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1046\/j.1600-6135.2003.00279.x","volume":"4","author":"L Fritsche","year":"2004","unstructured":"Fritsche L, Budde K, Dragun D, Einecke G, Diekmann F, Neumayer HH (2004) Testosterone concentrations and sirolimus in male renal transplant patients. Am J Transplant 4:130\u2013131","journal-title":"Am J Transplant"},{"key":"3474_CR53","volume":"7","author":"M Braun","year":"2012","unstructured":"Braun M, Young J, Reiner CS, Poster D, Krauer F, Kistler AD, Kristanto P, Wang X, Liu Y, Loffing J, Andreisek G, von Eckardstein A, Senn O, W\u00fcthrich RP, Serra AL (2012) Low-dose oral sirolimus and the risk of menstrual-cycle disturbances and ovarian cysts: analysis of the randomized controlled SUISSE ADPKD trial. PLoS One 7, e45868","journal-title":"PLoS One"},{"key":"3474_CR54","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s00467-013-2505-9","volume":"29","author":"L Pape","year":"2014","unstructured":"Pape L, Ahlenstiel T (2014) mTOR inhibitors in pediatric kidney transplantation. Pediatr Nephrol 29:1119\u20131129","journal-title":"Pediatr Nephrol"},{"key":"3474_CR55","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/petr.12147","volume":"17","author":"R Ganschow","year":"2013","unstructured":"Ganschow R, Pape L, Sturm E, Bauer J, Melter M, Gerner P, H\u00f6cker B, Ahlenstiel T, Kemper M, Brinkert F, Sachse MM, T\u00f6nshoff B (2013) Growing experience with mTOR inhibitors in pediatric solid organ transplantation. Pediatr Transplant 17:694\u2013706","journal-title":"Pediatr Transplant"},{"key":"3474_CR56","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s00467-013-2459-y","volume":"28","author":"B Kranz","year":"2013","unstructured":"Kranz B, Wingen AM, Vester U, Konig J, Hoyer PF (2013) Long-term side effects of treatment with mTOR inhibitors in children after renal transplantation. Pediatr Nephrol 28:1293\u20131298","journal-title":"Pediatr Nephrol"},{"key":"3474_CR57","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1007\/s00467-014-3027-9","volume":"30","author":"L Waele De","year":"2015","unstructured":"De Waele L, Lagae L, Mekahli D (2015) Tuberous sclerosis complex: the past and the future. Pediatr Nephrol 30:1771\u20131780","journal-title":"Pediatr Nephrol"},{"key":"3474_CR58","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S1470-2045(14)70489-9","volume":"15","author":"DN Franz","year":"2014","unstructured":"Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ, Berkowitz N, Anak O, Niolat J, Jozwiak S (2014) Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study. Lancet Oncol 15:1513\u20131520","journal-title":"Lancet Oncol"},{"key":"3474_CR59","doi-asserted-by":"crossref","unstructured":"Franz DN, Agricola K, Mays M, Tudor C, Care MM, Holland-Bouley K, Berkowitz N, Miao S, Peyrard S, Krueger DA (2015) Everolimus for subependymal giant cell astrocytoma: 5-year final analysis. Ann Neurol","DOI":"10.1002\/ana.24523"},{"key":"3474_CR60","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ejpn.2013.03.002","volume":"17","author":"K Kotulska","year":"2013","unstructured":"Kotulska K, Chmielewski D, Borkowska J, Jurkiewicz E, Kuczy\u0144ski D, Kmie\u0107 T, \u0141ojszczyk B, Dunin-W\u0105sowicz D, J\u00f3\u017awiak S (2013) Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. Eur J Paediatr Neurol 17:479\u2013485","journal-title":"Eur J Paediatr Neurol"},{"key":"3474_CR61","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/ndt\/gfu013","volume":"29","author":"JC Kingswood","year":"2014","unstructured":"Kingswood JC, Jozwiak S, Belousova ED, Frost MD, Kuperman RA, Bebin EM, Korf BR, Flamini JR, Kohrman MH, Sparagana SP, Wu JY, Brechenmacher T, Stein K, Berkowitz N, Bissler JJ, Franz DN (2014) The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1. Nephrol Dial Transplant 29:1203\u20131210","journal-title":"Nephrol Dial Transplant"},{"key":"3474_CR62","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S1474-4422(15)00069-1","volume":"14","author":"P Curatolo","year":"2015","unstructured":"Curatolo P, Moavero R, de Vries PJ (2015) Neurological and neuropsychiatric aspects of tuberous sclerosis complex. Lancet Neurol 14:733\u2013745","journal-title":"Lancet Neurol"},{"key":"3474_CR63","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/YCO.0000000000000136","volume":"28","author":"L Leclezio","year":"2015","unstructured":"Leclezio L, de Vries PJ (2015) Advances in the treatment of tuberous sclerosis complex. Curr Opin Psychiatr 28:113\u2013120","journal-title":"Curr Opin Psychiatr"},{"key":"3474_CR64","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/CAD.0000000000000207","volume":"26","author":"J Trelinska","year":"2015","unstructured":"Trelinska J, Dachowska I, Kotulska K, Fendler W, Jozwiak S, Mlynarski W (2015) Complications of mammalian target of rapamycin inhibitor anticancer treatment among patients with tuberous sclerosis complex are common and occasionally life-threatening. Anticancer Drugs 26:437\u2013442","journal-title":"Anticancer Drugs"},{"key":"3474_CR65","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/petr.12261","volume":"18","author":"M Ferraresso","year":"2014","unstructured":"Ferraresso M, Belingheri M, Ginevri F, Murer L, Dello Strologo L, Cardillo M, Parodi A, Ghirardo G, Guzzo I, Innocente A, Ghio L (2014) Three-year safety and efficacy of everolimus and low-dose cyclosporine in de novo pediatric kidney transplant patients. Pediatr Transplant 18:350\u2013356","journal-title":"Pediatr Transplant"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00467-016-3474-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-016-3474-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-016-3474-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-016-3474-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T04:39:42Z","timestamp":1718771982000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00467-016-3474-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,1]]},"references-count":65,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["3474"],"URL":"https:\/\/doi.org\/10.1007\/s00467-016-3474-6","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,1]]}}}